Giulia Casorati
Overview
Explore the profile of Giulia Casorati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
2143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cortellino S, Raveane A, Chiodoni C, Delfanti G, Pisati F, Spagnolo V, et al.
Cell Rep
. 2022 Aug;
40(8):111256.
PMID: 36001966
Immunotherapy is improving the prognosis and survival of cancer patients, but despite encouraging outcomes in different cancers, the majority of tumors are resistant to it, and the immunotherapy combinations are...
12.
Delfanti G, Cortesi F, Perini A, Antonini G, Azzimonti L, De Lalla C, et al.
Sci Immunol
. 2022 Aug;
7(74):eabn6563.
PMID: 35984893
Adoptive immunotherapy with T cells engineered with tumor-specific T cell receptors (TCRs) holds promise for cancer treatment. However, suppressive cues generated in the tumor microenvironment (TME) can hinder the efficacy...
13.
Faccani C, Rotta G, Clemente F, Fedeli M, Abbati D, Manfredi F, et al.
Life Sci Alliance
. 2022 Jun;
5(10).
PMID: 35724271
We describe a multi-step high-dimensional (HD) flow cytometry workflow for the deep phenotypic characterization of T cells infiltrating metastatic tumor lesions in the liver, particularly derived from colorectal cancer (CRC-LM)....
14.
Delfanti G, Dellabona P, Casorati G, Fedeli M
Front Med (Lausanne)
. 2022 May;
9:897750.
PMID: 35615083
Invariant Natural Killer T (iNKT) cells are T lymphocytes expressing a conserved semi-invariant TCR specific for lipid antigens (Ags) restricted for the monomorphic MHC class I-related molecule CD1d. iNKT cells...
15.
Fedeli M, Kuka M, Finardi A, Albano F, Vigano V, Iannacone M, et al.
Clin Transl Immunology
. 2021 Sep;
10(9):e1321.
PMID: 34584693
Objective: miR-21 is highly expressed in iNKT and activated T cells, but its T-cell autonomous functions are poorly defined. We sought to investigate the role of miR-21 in the development...
16.
Consonni M, Garavaglia C, Grilli A, De Lalla C, Mancino A, Mori L, et al.
Nat Commun
. 2021 Aug;
12(1):4844.
PMID: 34381053
Acute leukemia relapsing after chemotherapy plus allogeneic hematopoietic stem cell transplantation can be treated with donor-derived T cells, but this is hampered by the need for donor/recipient MHC-matching and often...
17.
Grioni M, Brevi A, Cattaneo E, Rovida A, Bordini J, Bertilaccio M, et al.
Blood Adv
. 2021 Jul;
5(14):2817-2828.
PMID: 34269799
Chronic lymphocytic leukemia (CLL) is caused by the progressive accumulation of mature CD5+ B cells in secondary lymphoid organs. In vitro data suggest that CD4+ T lymphocytes also sustain survival...
18.
Manfredi F, Abbati D, Cianciotti B, Stasi L, Potenza A, Ruggiero E, et al.
Eur J Immunol
. 2021 Jun;
51(8):1992-2005.
PMID: 34081326
The phenotype of infused cells is a major determinant of Adoptive T-cell therapy (ACT) efficacy. Yet, the difficulty in deciphering multiparametric cytometry data limited the fine characterization of cellular products....
19.
Tanzi M, Consonni M, Falco M, Ferulli F, Montini E, Pasi A, et al.
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33808051
The limited efficacy of Natural Killer (NK) cell-based immunotherapy results in part from the suboptimal expansion and persistence of the infused cells. Recent reports suggest that the generation of NK...
20.
Guerrouahen B, Elnaggar M, Al-Mohannadi A, Kizhakayil D, Bonini C, Benjamin R, et al.
Front Immunol
. 2021 Feb;
11:589381.
PMID: 33584653
The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT)....